Page results
-
How UCLH uses clinical data in research.
-
The aim of the Integrated Care Operations is to support the development of patient centred co-ordinated care for UCLH patients through collaborative working across the organisation and with the community, social and primary care.
-
Fears that people with high blood pressure are more at risk from severe Covid-19 because it is easier for the virus to enter their cells and tissues have been laid to rest, thanks to research involving UCLH.
-
We have worked with the North Central London Cancer Alliance to create a series of wellbeing videos to help those with cancer manage the side effects of treatment. On this page you can find out more about managing fatigue and pain, and how to improve your sleep.
-
This easy read page offers advice for patients on managing pain after an operation.
-
Alison Clements, head of operations, patient flow and EPRR, has received a medal in recognition of her work to support NHS preparations for the Coronation of Charles III and Camilla last May.
-
The musculoskeletal (MSK) outpatient therapy service at University College Hospital provides assessment and treatment of patients for a variety of specialities including orthopaedic, rheumatology, hand therapy, women’s health, orthotic, podiatry and spinal non-operative and operative patients with musculoskeletal dysfunction.
-
UCLH Charity is delighted to announce that the Dangoor Family’s Exilarch’s Foundation has pledged a £1.2m gift to support the next phase of the development of the CAR T programme at University College London Hospitals NHS Foundation Trust (UCLH). The CAR T Speed Release Project aims to reduce the time between extracting patient’s stem cells and injecting re-engineered CAR T cells back into patients with cancer to fight cancer cells.
-
Information for service users about the RESPOND service for refugees and asylum seekers.
-
Patient information for Red Cell Network patients
File results
-
FOI/2022/0212 - Clotting disorders medication
-
FOI/2022/0214 - Prostate Cancer (Summary Funding and costs of Xtandi (Enzalutamide) trial: NCT00974311) Xtandi (Enzalutamide) trial, NCT00974311
-
FOI/2022/0217 - Medications for dermatological conditions
-
FOI/2022/0221 - Asthma medications
-
FOI/2022/0223 - Policies/ procedures for management of patients with chest pain
-
FOI/2022/0224 - Procurement for physiotherapy, occupational therapy, pharmacy, radiography, speech and language therapy and sterile services
-
FOI/2022/0226 - Treatments for Haemophilia A
-
FOI/2022/0227 - Number of cancer trackers and cancer MDT co-ordinators at Trust
-
FOI/2022/0230 - Fabry, Gaucher and Pompe diseases drug treatments
-
FOI/2022/0232 - Number of patients who have died while waiting for elective care